GlycoVaxyn's Series B Round

GlycoVaxyn raised a round of funding on March 17, 2009.

GlycoVaxyn is a clinical stage biopharmaceutical company focused on the development and manufacture of next-generation bioconjugate vaccines utilizing its proprietary recombinant DNA technology. Glyco…

Articles about GlycoVaxyn's Series B Round: